Table 6.
Statistical Analysis (Multivariate Analysis) of Clinicopathological Parameter and Labeling Indexes of Immunohistochemical Staining in Leiomyosarcoma
| Clinical outcome | Parameter | R.R. | C.I. | P value |
|---|---|---|---|---|
| Recurrence-free survival period | Cyclin A* | 18.4 | 1.2–282.1 | <0.02 |
| Mitosis† | 6.96 | 1.06–45.7 | <0.05 | |
| Size‡ | 3.13 | 0.83–12.0 | N.S.∥ | |
| Location§ | 1.01 | 0.29–3.51 | N.S.∥ | |
| Cyclin E¶ | 0.36 | 0.11–1.18 | N.S.∥ | |
| Metastasis-free survival period | Size | 10.4 | 1.06–102.0 | <0.05 |
| Cyclin E | 1.49 | 0.26–8.54 | N.S.∥ | |
| Cyclin A | 8.90 | 0.22–360.0 | N.S.∥ | |
| Mitosis | 1.26 | 0.31–5.47 | N.S.∥ | |
| Overall survival period | Size | 10.9 | 1.14–104.1 | <0.05 |
| Cyclin E | 6.81 | 1.01–45.9 | <0.05 | |
| Cyclin A | 5.86 | 0.15–230.7 | N.S.∥ | |
| Mitosis | 3.53 | 0.53–23.5 | N.S.∥ |
R.R., relative risk; C.I., 95% confidence interval.
*Cyclin A; < or = >10%.
†Mitosis; < or = > 6 mitoses/10 high-power-field.
‡Size; < or = >5 cm.
§Location; cutis/deeper.
¶Cyclin E; 0 or > 0%.
∥N.S.; not significant.
Note: Since cutaneous leiomyosarcoma never metastasizes, we analyzed recurrence in all cases of LMS and metastasis and overall survival in deep LMS cases. Accordingly, for the analysis of metastasis and overall survival, parameter “location” was not included.